We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Genentech’s Lucentis for Additional Indication in DME
FDA Approves Genentech’s Lucentis for Additional Indication in DME
August 17, 2012
The FDA has approved Genentech’s Lucentis for an additional indication in diabetic macular edema (DME), making it the first and only agency-approved treatment for the condition.